Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, Affymetrix Lead Gainers in Short Trade Week

Shares in Sequenom and Affymetrix rose 5.8 percent and 5.1 percent, respectively, to lead gainers in the BCW Index for the four-day trading week ended Tuesday. There was no trading in the US on Monday due to the Memorial Day holiday. It was the second week in a row that Sequenom posted a significant increase in its share price.
 
Caliper Life Sciences led the 17 stocks that declined for the trading period, falling 5.8 percent.
 
Overall, the Index fell .4 percent. In comparison, the Dow Jones Industrial Average slipped .1 percent, while the Nasdaq and Nasdaq Biotech Index both dropped .6 percent.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(May 29, 2007)
Starting Price
(
May 22, 2007)
% change
Affymetrix
AFFX
26.26
24.98
5.12
Agilent
A
38.32
38.54
-0.57
Applied Biosystems
ABI
28.57
28.76
-0.66
Beckman
BEC
65.89
67.42
-2.27
Becton Dickinson
BDX
76.58
76.91
-0.43
Bio-Rad
BIO
74.47
73.91
0.76
Bruker
BRKR
8.51
8.89
-4.27
Caliper
CALP
4.7
4.99
-5.81
Cepheid
CPHD
11.67
11.8
-1.10
Illumina
ILMN
32.63
32.66
-0.09
Invitrogen
IVGN
71.82
72.75
-1.28
Luminex
LMNX
12.81
13.23
-3.17
MDS
MDZ
20.07
20.14
-0.35
Millipore
MIL
74.68
75.54
-1.14
PerkinElmer
PKI
26.1
25.65
1.75
Qiagen
QGEN
17.21
17.32
-0.64
Sequenom
SQNM
4.17
3.94
5.84
Sigma-Aldrich
SIAL
43.02
43.54
-1.19
Stratagene
STGN
10.85
10.89
-0.37
Thermo
TMO
54.06
53.69
0.69
Third Wave
TWTI
5.96
5.98
-0.33
Waters
WAT
60.57
60.7
-0.21
BCW Index Average  
34.95
35.10
-0.43
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.